CSIMarket
 


Veru Inc   (VERU)
Other Ticker:  
 
 

VERU's Capital Expenditures Growth by Quarter and Year

Veru Inc 's Capital Expenditures results by quarter and year




VERU Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter September 0.21 0.15 0.22 0.03
III Quarter June 0.03 0.10 0.14 0.02
II Quarter March 0.14 0.19 0.00 0.03
I Quarter December 0.29 0.30 0.01 0.02
FY   0.67 0.74 0.37 0.10



VERU Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Veru Inc reported Capital Expenditures rise of 41.92% year on year in the fourth quarter 2023, to $ 0.21 millions, this is lower than Veru Inc 's recent average Capital Expenditures surge of 779.36%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 63 other companies have achieved higher Capital Expenditures growth. While Veru Inc ' s Capital Expenditures jump of 41.92% ranks overall at the positon no. 837 in the fourth quarter 2023.




VERU Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter September 41.92 % -31.82 % 633.33 % 0 %
III Quarter June -70 % -28.57 % 600 % -71.43 %
II Quarter March -26.32 % - - -
I Quarter December -3.33 % 2900 % -50 % -
FY   -9.07 % 100 % 270 % 0 %

Financial Statements
Veru Inc 's fourth quarter 2023 Capital Expenditures $ 0.21 millions VERU's Income Statement
Veru Inc 's fourth quarter 2022 Capital Expenditures $ 0.15 millions Quarterly VERU's Income Statement
New: More VERU's historic Capital Expenditures Growth >>


VERU Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter September 609.58 % 50 % 57.14 % 50 %
III Quarter June -78.57 % -47.37 % - -33.33 %
II Quarter March -51.72 % -36.67 % - 50 %
I Quarter December 93.33 % 36.36 % -66.67 % -33.33 %
FY (Year on Year)   -9.07 % 100 % 270 % 0 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #64
Healthcare Sector #166
Overall #837

Capital Expenditures Y/Y Growth Statistics
High Average Low
5137.61 % 779.36 % -100 %
(Jun 30 2017)   (Dec 31 2018)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #64
Healthcare Sector #166
Overall #837
Capital Expenditures Y/Y Growth Statistics
High Average Low
5137.61 % 779.36 % -100 %
(Jun 30 2017)   (Dec 31 2018)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Veru Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
11437.89 % 502.86 % -100 %
(Jun 30 2019)  


VERU's IV. Quarter Q/Q Capital Expenditures Comment
Veru Inc achieved in the IV. Quarter 2023 above company average sequential Capital Expenditures doubling of 609.58%, to $ 0.21 millions, from $0.03 millions in the third quarter.
Veru Inc is undergoing a remarkable growth, with reporting higher then regular gain, and additionally improving pace, Alejandro Fernández, an industry advisor said.

Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Veru Inc 's Capital Expenditures growth quarter on quarter, overall rank is 107.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #9
Healthcare Sector #22
Overall #107
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #9
Healthcare Sector #22
Overall #107
Capital Expenditures Q/Q Growth Statistics
High Average Low
11437.89 % 502.86 % -100 %
(Jun 30 2019)  


VERU's IV. Quarter Q/Q Capital Expenditures Comment
Veru Inc achieved in the IV. Quarter 2023 above company average sequential Capital Expenditures doubling of 609.58%, to $ 0.21 millions, from $0.03 millions in the third quarter.
VERU is going from strength to strength, with claiming better then regular gain, but also improving rate.

Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Veru Inc 's Capital Expenditures growth quarter on quarter, overall rank is 107.


Veru Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 0.67 $ 0.60 $ 0.67 $ 0.72 $ 0.73
Y / Y Capital Expenditures Growth (TTM) -9.19 % -25.4 % -21.03 % 6.66 % 94.62 %
Year on Year Capital Expenditures Growth Overall Ranking # 261 # 68 # 8 # 39 # 0
Seqeuential Capital Expenditures Change (TTM) 10.65 % -10.57 % -6.09 % -2.27 % -9.1 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1554 # 1575 # 734 # 347 # 0




Cumulative Capital Expenditures growth Comment
Veru Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Veru Inc 's annual Capital Expenditures decrease would be -9.19% year on year to $1 millions.

In the Healthcare sector 58 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 68 to 261.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1248.09 %
167.04 %
-95.29 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 70
Healthcare Sector # 59
Overall # 261

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1248.09 %
167.04 %
-95.29 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 70
Sector # 210
S&P 500 # 1554
Cumulative Capital Expenditures growth Comment
Veru Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Veru Inc 's annual Capital Expenditures drop would be -9.19% year on year to $1 millions.

In the Healthcare sector 58 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 68 to 261.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1248.09 %
167.04 %
-95.29 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 70
Healthcare Sector # 59
Overall # 261

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1248.09 %
167.04 %
-95.29 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 70
Sector # 210
S&P 500 # 1554




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
VERU's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for VERU's Competitors
Capital Expenditures Growth for Veru Inc 's Suppliers
Capital Expenditures Growth for VERU's Customers

You may also want to know
VERU's Annual Growth Rates VERU's Profitability Ratios VERU's Asset Turnover Ratio VERU's Dividend Growth
VERU's Roe VERU's Valuation Ratios VERU's Financial Strength Ratios VERU's Dividend Payout Ratio
VERU's Roa VERU's Inventory Turnover Ratio VERU's Growth Rates VERU's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Acadia Healthcare Company Inc 67.72%$ 67.720 millions
Blueprint Medicines Corporation67.63%$ 67.632 millions
Henry Schein Inc66.67%$ 66.667 millions
West Pharmaceutical Services Inc 65.74%$ 65.744 millions
Schrodinger Inc 64.01%$ 64.009 millions
Veracyte inc 63.48%$ 63.477 millions
Radnet Inc 60.93%$ 60.932 millions
Moderna Inc 57.30%$ 57.303 millions
Eli Lilly And Company57.21%$ 57.210 millions
Agilon Health Inc 57.20%$ 57.201 millions
Vor Biopharma Inc 56.04%$ 56.040 millions
Lifevantage Corp55.85%$ 55.846 millions
Yunhong Green Cti Ltd 55.56%$ 55.556 millions
Amgen Inc 55.00%$ 55.000 millions
Vivos Therapeutics Inc 54.00%$ 54.000 millions
Beigene ltd 53.97%$ 53.969 millions
Hyperfine Inc 52.02%$ 52.023 millions
Intuitive Surgical Inc 51.57%$ 51.567 millions
Precision Optics Corporation Inc 49.16%$ 49.164 millions
Biogen Inc 48.22%$ 48.223 millions
Acorda Therapeutics Inc 46.67%$ 46.667 millions
Femasys Inc 46.54%$ 46.543 millions
Staar Surgical Company46.42%$ 46.421 millions
Livanova Plc44.31%$ 44.314 millions
Seres Therapeutics Inc 44.11%$ 44.106 millions
Abcellera Biologics Inc 43.95%$ 43.947 millions
Eyepoint Pharmaceuticals Inc 43.57%$ 43.573 millions
Irhythm Technologies Inc 43.49%$ 43.486 millions
Veru Inc 43.05%$ 43.054 millions
Integra Lifesciences Holdings Corp42.85%$ 42.851 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com